Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1199921 | 0.83 | GLA (0.46) | ALDH1A1L3MBTL1GAAGLACA12 | |
| SCHEMBL17557750 | 0.83 | CNR1 (0.36) | TSHRALDH1A1HSD17B10MAPTTP53 | |
| SCHEMBL17557666 | 0.80 | CYP3A4 (0.40) | TSHRALDH1A1HSD17B10MAPTTP53 | |
| SCHEMBL21987295 | 0.79 | ALDH1A1 (0.48) | TSHRALDH1A1HSD17B10MAPTTP53 | |
| Hydrochloric Acid SCHEMBL17557631 | 0.79 | CYP3A4 (0.40) | TSHRALDH1A1HSD17B10MAPTTP53 | |
| SCHEMBL19201201 | 0.78 | NCF1 (0.39) | TSHRALDH1A1HSD17B10MAPTTP53 | |
| SCHEMBL6433710 | 0.77 | L3MBTL1 (0.51) | TSHRALDH1A1L3MBTL1GAAKMT2A | |
| Hydrochloric Acid SCHEMBL19183246 | 0.77 | CYP3A4 (0.38) | TSHRALDH1A1HSD17B10MAPTTP53 | |
| SCHEMBL10167818 | 0.76 | CA1 (0.38) | TSHRALDH1A1HSD17B10MAPTL3MBTL1 | |
| SCHEMBL21798263 | 0.76 | KCNQ3 (0.33) | TSHRHSD17B10GAACA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2025-11-11 | — | — | US | disclosed |
| EP-4479388-A1 | ANTIVIRAL NAPHTHYRIDINONE COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023154905-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154905-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-02-16 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | NOVARTIS AG (CH) | 2021-07-27 | — | — | US | disclosed |
| EP-3849979-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | Novartis AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| CN-112996789-A | Antiviral pyridopyrazinedione compounds | 诺华股份有限公司 | 2021-06-18 | — | — | CN | disclosed |
| WO-2020053654-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-19 | — | — | WO | disclosed |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124198-A1 | ANTIVIRAL PYRAZOLOPYRIDINONE COMPOUNDS | ZC3HAV1, CCR1, CCR6 | TSHR 2194/4885ALDH1A1 3001/4885HSD17B10 2339/4885 |
| US-12466821-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | TSHR 4291/4885ALDH1A1 1714/4885HSD17B10 1400/4885 |
| US-20230052629-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | TSHR 4291/4885ALDH1A1 1714/4885HSD17B10 1400/4885 |
| US-11072610-B2 | Antiviral pyridopyrazinedione compounds | ZC3HAV1, IL5, TYMP | TSHR 4291/4885ALDH1A1 1714/4885HSD17B10 1400/4885 |
| US-20200079772-A1 | ANTIVIRAL PYRIDOPYRAZINEDIONE COMPOUNDS | ZC3HAV1, IL5, TYMP | TSHR 4291/4885ALDH1A1 1714/4885HSD17B10 1400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.